valu usd unless otherwis note
better fear earn
view amerisourc report result in-lin
expect oper incom view better fear
investor given continu challeng pharmedium
result report result exceed forecast
consensu revenu ep revenu beat forecast
street stronger expect core
distribut growth contribut hd smith rite aid
store acquisit adjust oper profit in-lin
forecast ep exceed forecast street
oper incom line issu pharmedium lash
off-set stronger expect revenu exclus
pharmedium remedi expens adjust number beat
vs number driven lower tax benefit
pharmedium recoveri push manag expect
impact memphi pharmedium facil extend
minim oper incom contribut expect
facil revis forecast pharmedium larg account
lower guidanc manag state
ebit guidanc reduct due distribut segment
mainli pharmedium impact financi due foregon
gross profit contribut memphi plant exclud
remedi cost adjust financi without larg
competitor outsourc compound space believ
volum gone back in-hous could come back pharmedium
oper resum memphi facil
adjust estim adjust estim reflect tax
driven beat lower forecast pharmedium lash
remaind higher revenu forecast core specialti
drug distribut strength also adjust estim reflect
consolid profarma specialti jv brazil revis
revenu estim ep estim
increas ep estim reflect tax beat off-set
challeng second half well chang
report brazilian invest
maintain sector perform maintain sector perform share
follow quarter larg in-lin expect
tax benefit price target unchang base
price-to-earnings multipl appli ep estim
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
believ share like multipl rang bound
investor get visibl gener drug price
bottom oper earn growth resum
pressur last
month multipl issu relat drug price
weigh result expect backdrop
improv next month howev believ
best-posit wholesal
meet earn target given conserv guidanc
relationship walgreen though note
rel strength seem reflect current share
estim gener profit
core us drug distribut busi sale gener
drug past two year seen
price gener drug deflat high-single-digit mid-
teen percentag rate profit dollar contribut
fall slightli lower rate gener deflat continu
high-single-digit pace higher believ
volum growth abl
grow earn segment though may best
posit creat spread price fall
upsid risk sector perform rate share
includ stabil drug price environ
could caus earn estim stabil like drive
multipl expans close market multipl
downsid risk sector perform rate includ
acceler drug price deterior gener
market potenti client loss wholesal
sell-sid price compress larger pharmaci
custom gpo
bloomberg capit market estim upside/downside/target
price target share equal
ep estim use multipl reflect
averag forward trade multipl share
upsid scenario share base
ep estim higher base case price-to-earnings
multipl appli ep scenario upsid scenario
ep better ep growth could
driven success partnership walgreen increas
volum across brand gener drug success capit
deploy level gener price deflat
forward multipl repres high end
normal trade rang drug wholes space
multipl like get neg
downsid scenario share base
ep estim base case price-to-earnings multipl
appli ep scenario downsid scenario
ep lower-than-expect ep could
driven worse-than-expect price environ
lower-than-expect brand gener volum lack
avail opportun forward multipl
like get posit share
result varianc tabl act commentspharmaceut hd smith roll adj adj adj modest outperformanceoth adj gross distribut consol severance- intagibles- oper adj adj adj oper numberdistribut adj adj total adj op loss- expens lineincom tax per beat larg taxconsensu number share marginoper marginamerisourcebergenbp changebp chang healthcar technolog distribut
price target share support sector perform rate equal
ep estim use multipl reflect averag
forward trade multipl share
risk rate price target
forese upsid downsid risk sector perform rate share
upsid risk includ stabil drug price environ could caus earn
estim stabil like drive multipl expans close market multipl
downsid risk includ acceler drug price deterior gener market
potenti client loss wholesal sell-sid price compress
larger pharmaci custom gpo
pharmaceut distribut consult compani oper
distribut segment
distribut segment includ amerisourcebergen drug corpor abdc
compani amerisourcebergen consult servic abc world courier mwi
veterinari suppli busi partnership walgreen boot
allianc global drug sourc distribut product locat
good sold
segment revenu
segment revenu
amort intang
revenu
segment revenu
segment revenu
incom discontinu oper net tax
net loss attribut non-controlling interest
net incom attribut
earn per share continu oper
weight average number share
